CR20150124A - Formulación de una cápsula farmcéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa - Google Patents
Formulación de una cápsula farmcéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasaInfo
- Publication number
- CR20150124A CR20150124A CR20150124A CR20150124A CR20150124A CR 20150124 A CR20150124 A CR 20150124A CR 20150124 A CR20150124 A CR 20150124A CR 20150124 A CR20150124 A CR 20150124A CR 20150124 A CR20150124 A CR 20150124A
- Authority
- CR
- Costa Rica
- Prior art keywords
- hmg
- formulation
- inhibitor
- pharmaceutical capsule
- irbesartan
- Prior art date
Links
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 229960002198 irbesartan Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulgan una formulación de una cápsula farmacéutica compuesta que comprende 1) una unidad de irbesartan independiente que comprende irbesartan o una de sus sales aceptables desde el punto de vista farmacéutico; y 2) una unidad independiente de inhibidor de la HMG-CoA reductasa que comprende un inhibidor de la HMG-CoA reductasa o una de sus sales aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120096036A KR20140030505A (ko) | 2012-08-31 | 2012-08-31 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| PCT/KR2013/007841 WO2014035190A1 (en) | 2012-08-31 | 2013-08-30 | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150124A true CR20150124A (es) | 2015-04-24 |
Family
ID=50183919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150124A CR20150124A (es) | 2012-08-31 | 2015-03-11 | Formulación de una cápsula farmcéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20150231085A1 (es) |
| EP (1) | EP2890371A4 (es) |
| JP (1) | JP2015526509A (es) |
| KR (1) | KR20140030505A (es) |
| CN (1) | CN104602678A (es) |
| AR (1) | AR092385A1 (es) |
| AU (1) | AU2013309688A1 (es) |
| BR (1) | BR112015004091A2 (es) |
| CA (1) | CA2882738A1 (es) |
| CL (1) | CL2015000363A1 (es) |
| CO (1) | CO7350622A2 (es) |
| CR (1) | CR20150124A (es) |
| DO (1) | DOP2015000042A (es) |
| EA (1) | EA201590474A1 (es) |
| EC (1) | ECSP15010617A (es) |
| IL (1) | IL237425A0 (es) |
| IN (1) | IN2015DN01738A (es) |
| MA (1) | MA37953A1 (es) |
| MX (1) | MX2015002591A (es) |
| NI (1) | NI201500028A (es) |
| PE (1) | PE20150402A1 (es) |
| PH (1) | PH12015500395A1 (es) |
| RU (1) | RU2015111523A (es) |
| SG (1) | SG11201500580QA (es) |
| TW (1) | TW201414511A (es) |
| UY (1) | UY35000A (es) |
| WO (1) | WO2014035190A1 (es) |
| ZA (1) | ZA201502157B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| EP3184103A1 (en) * | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| WO2019023198A1 (en) * | 2017-07-25 | 2019-01-31 | Plexxikon Inc. | FORMULATION OF A COMPOUND MODULATING KINASES |
| CN110237070A (zh) * | 2019-05-10 | 2019-09-17 | 辽宁大学 | 厄贝沙坦在制备降血脂药物中的应用 |
| CN116669715A (zh) * | 2020-11-18 | 2023-08-29 | Fb-Hrs有限责任公司 | 含有多非利特和美西律的组合物及其应用 |
| CN113476423A (zh) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| CA2568640C (en) * | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| WO2008010008A2 (en) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Cardiovascular combinations using rennin-angiotensin inhibitors |
| US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
| CN101980701A (zh) * | 2008-03-28 | 2011-02-23 | 菲尔若国际公司 | 用于预防心血管疾病的胶囊 |
| KR20090114320A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
| AU2010242938A1 (en) * | 2009-04-30 | 2011-11-17 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| WO2012010977A2 (en) * | 2010-07-21 | 2012-01-26 | Nucitec S.A. De C.V. | Single daily dosage form for prevention and treatment of metabolic syndrome |
-
2012
- 2012-08-31 KR KR1020120096036A patent/KR20140030505A/ko not_active Ceased
-
2013
- 2013-08-29 AR ARP130103082A patent/AR092385A1/es unknown
- 2013-08-30 SG SG11201500580QA patent/SG11201500580QA/en unknown
- 2013-08-30 UY UY0001035000A patent/UY35000A/es not_active Application Discontinuation
- 2013-08-30 RU RU2015111523A patent/RU2015111523A/ru not_active Application Discontinuation
- 2013-08-30 AU AU2013309688A patent/AU2013309688A1/en not_active Abandoned
- 2013-08-30 PE PE2015000255A patent/PE20150402A1/es not_active Application Discontinuation
- 2013-08-30 CN CN201380045368.3A patent/CN104602678A/zh active Pending
- 2013-08-30 MX MX2015002591A patent/MX2015002591A/es unknown
- 2013-08-30 JP JP2015529684A patent/JP2015526509A/ja active Pending
- 2013-08-30 CA CA2882738A patent/CA2882738A1/en not_active Abandoned
- 2013-08-30 EP EP13834178.9A patent/EP2890371A4/en not_active Withdrawn
- 2013-08-30 BR BR112015004091A patent/BR112015004091A2/pt not_active IP Right Cessation
- 2013-08-30 TW TW102131242A patent/TW201414511A/zh unknown
- 2013-08-30 WO PCT/KR2013/007841 patent/WO2014035190A1/en not_active Ceased
- 2013-08-30 IN IN1738DEN2015 patent/IN2015DN01738A/en unknown
- 2013-08-30 EA EA201590474A patent/EA201590474A1/ru unknown
- 2013-08-30 US US14/420,953 patent/US20150231085A1/en not_active Abandoned
-
2015
- 2015-02-16 CL CL2015000363A patent/CL2015000363A1/es unknown
- 2015-02-24 PH PH12015500395A patent/PH12015500395A1/en unknown
- 2015-02-25 IL IL237425A patent/IL237425A0/en unknown
- 2015-02-26 DO DO2015000042A patent/DOP2015000042A/es unknown
- 2015-02-27 NI NI201500028A patent/NI201500028A/es unknown
- 2015-03-11 CR CR20150124A patent/CR20150124A/es unknown
- 2015-03-13 CO CO15058341A patent/CO7350622A2/es unknown
- 2015-03-20 EC ECIEPI201510617A patent/ECSP15010617A/es unknown
- 2015-03-27 MA MA37953A patent/MA37953A1/fr unknown
- 2015-03-30 ZA ZA2015/02157A patent/ZA201502157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150231085A1 (en) | 2015-08-20 |
| BR112015004091A2 (pt) | 2017-07-04 |
| CN104602678A (zh) | 2015-05-06 |
| AU2013309688A1 (en) | 2015-02-26 |
| ECSP15010617A (es) | 2015-12-31 |
| TW201414511A (zh) | 2014-04-16 |
| EA201590474A1 (ru) | 2015-06-30 |
| PH12015500395A1 (en) | 2015-04-27 |
| IL237425A0 (en) | 2015-04-30 |
| CO7350622A2 (es) | 2015-08-10 |
| WO2014035190A1 (en) | 2014-03-06 |
| AR092385A1 (es) | 2015-04-22 |
| KR20140030505A (ko) | 2014-03-12 |
| ZA201502157B (en) | 2016-10-26 |
| CA2882738A1 (en) | 2014-03-06 |
| SG11201500580QA (en) | 2015-02-27 |
| UY35000A (es) | 2014-03-31 |
| MA37953A1 (fr) | 2017-01-31 |
| RU2015111523A (ru) | 2016-10-20 |
| IN2015DN01738A (es) | 2015-05-29 |
| JP2015526509A (ja) | 2015-09-10 |
| CL2015000363A1 (es) | 2015-06-05 |
| MX2015002591A (es) | 2015-06-10 |
| DOP2015000042A (es) | 2015-04-30 |
| EP2890371A4 (en) | 2016-04-06 |
| NI201500028A (es) | 2017-01-04 |
| EP2890371A1 (en) | 2015-07-08 |
| PE20150402A1 (es) | 2015-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| CO6351777A2 (es) | Compuestos de tetraciclina sustituidod con fluor en c7 | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| CR20120545A (es) | Formulación farmacéutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| EP2483770A4 (en) | DYNAMIC IMAGE DISPLAY | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| GT201300159A (es) | Composiciones y metodos para modular el fxr | |
| UY32605A (es) | Agentes antiinflamatorios como compuestos virostáticos | |
| UY35000A (es) | ?formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa?. | |
| UA111475C2 (uk) | Способи лікування із застосуванням ліпідних сполук | |
| EP2651401A4 (en) | PHARMACEUTICAL COMPOSITION FORMULATION WITH AN HMG-COA REDUCTASE INHIBITOR AND ASPIRIN | |
| ECSP15050273A (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
| ES2530436T3 (es) | Combinación | |
| EP3025708A4 (en) | COMPLEX FORMULATION WITH DELAYED METFORMIN AND IMMEDIATELY RELEASED HMG COA REDUCTASE INHIBITOR | |
| CR20150115A (es) | Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio | |
| CL2012003661A1 (es) | Composición farmacéutica de liberación sostenida que comprende un compuesto derivado de 2-feniltiazol; y uso en el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal. | |
| JO3298B1 (ar) | مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt | |
| ES2524645B1 (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
| CR20130288A (es) | Comprimido farmacéutico de liberación controlada para administración oral | |
| TH1501001042A (th) | สูตรผสมแคปซูลประกอบแต่งทางเภสัชกรรมที่ประกอบรวมด้วยเออร์เบซาร์แทน และตัวยับยั้ง hmg-coa รีดัคเทส |